Evidence map›Paper›PMID 39266320›Full record

ArticleBMJ open2024

Guideline concordant screening and monitoring of extrapyramidal symptoms in patients prescribed antipsychotic medication: a protocol for a systematic literature review and narrative synthesis.

Rebekah Aubry, Thomas Hastings, Micheal Morgan, Jacqueline Hastings, Marie Bolton, Maura Grummell, Sinead Killeen, Cathal Coyne, Risa Shorr, Marco Solmi

Abstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rebekah AubryDepartment of Psychiatry, Lucena Clinic Services, Dublin, Ireland rebekah.aubry@sjog.ie.ORCID 0009-0008-8045-1704
Thomas HastingsDepartment of Psychiatry, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-7777-0981
Micheal MorganDepartment of Psychiatry, South Louth CAMHS, Drogheda, Ireland.ORCID 0009-0001-5954-4702
Jacqueline HastingsSchool of Medicine, UCD, Dublin, Ireland.
Marie BoltonDepartment of Child and Adolescent Psychiatry, St Vincent's Hospital Fairview, Dublin, Ireland.
Maura GrummellDepartment of Psychiatry, Mater Misericordiae University Hospital, Dublin, Ireland.
Sinead KilleenDepartment of Psychiatry, Lucena Clinic Services, Dublin, Ireland.
Cathal CoyneDepartment of Child and Adolescent Psychiatry, West Kildare CAMHS Linn Dara, Abbeylands Clane, Ireland.
Risa ShorrLearning Services, Ottawa Hospital, Ottawa, Ontario, Canada.
Marco SolmiOttawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0003-4877-7233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGiven the increasing rates of antipsychotic use in multiple psychiatric conditions, greater attention to the assessment, monitoring and documentation of their side effects is warranted. While a significant degree of attention has been provided to metabolic side effect monitoring, comparatively little is known about how clinicians screen for, document and monitor the motor side effects of antipsychotics (ie, parkinsonism, akathisia, dystonia and dyskinesias, collectively 'extrapyramidal side effects', EPS). This review aims to systematically assess the literature for insights into current trends in EPS monitoring practices within various mental health settings globally. METHODS AND ANALYSIS: An electronic search will be performed using the OVID Medline, PubMed, Embase, CINAHL and APA PsycINFO databases for studies published in the last quarter century (1998 to present day). Two independent reviewers will conduct the initial title and abstract screenings, using predetermined criteria for inclusion and exclusion. A third reviewer will resolve disagreements if consensus cannot be reached. If selected for inclusion, full-text data extraction will then be conducted using a pilot-tested data extraction form. Quality assessment will be conducted for all included studies using a modified version of the Quality Improvement Minimum Quality Criteria Set. A narrative synthesis and summary of the data will be provided. All stages of the review process will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. ETHICS AND DISSEMINATION: Ethical approval is not required. Findings will be peer reviewed, published and shared verbally, electronically and in print with interested clinicians and will also be presented as posters or talks at relevant medical conferences and meetings. PROSPERO REGISTRATION NUMBER: CRD42023482372.

Indexed as

Antipsychotic AgentsBasal Ganglia DiseasesSystematic Reviews as TopicHumansPractice Guidelines as TopicResearch DesignAntipsychotic AgentsProtocols & guidelinesPSYCHIATRYSchizophrenia & psychotic disordersSystematic Review

Identifiers

PMID39266320
PMCPMC11404193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.